Bayer Extraneal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer's peritoneal dialysis (PD) solution Extraneal is approved Dec. 20. Extraneal contains a novel osmotic agent (a polymer of glucose) that the firm says offers the potential for increased removal of fluid from the blood stream over currently available 1.5% and 2.5% dextrose solutions. In clinical trials, Extraneal showed higher net ultrafiltration than both dextrose solutions, as well as higher creatinine and urea nitrogen clearances than 2.5% dextrose. Extraneal is indicated for a single daily exchange for the long dwell (8- to 16-hours) during continuous ambulatory PD or automated PD for the management of chronic renal failure. Bayer is working on educational programs regarding potential effects on glucose tests as a postmarketing commitmen
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.